ORKA-001: a novel half-life extended IL-23p19 monoclonal antibody Oruka plans to initiate a Phase 1 trial of ORKA-001 in the first quarter of 2025, which was accelerated from the first half of 2025.

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisTwo trials for ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024 ...

Elevated IL-10 in diabetes causes capillary obstruction, linked to cognitive deficits. Blocking IL-10 receptors shows promise for improving brain function.

A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) ⎯ a potent immune-boosting protein that holds promise for cancer treatment ⎯ loses ...

OSE Therapeutics SA has reported positive data for lusvertikimab in a phase II trial in ulcerative colitis, boosting the ...

Dillon Gabriel threw for three touchdowns and ran for another, and top-ranked Oregon routed No. 20 Illinois 38-9 on Saturday to remain undefeated. Gabriel finished 18-of-26 for 291 yards and ...

The Oregon Ducks – 7-0, having dominated Big Ten Play and now ranked No. 1 in the nation – appear something close to unstoppable going into Saturday's game with No. 20 Illinois at Autzen ...